Literature DB >> 26646805

Delineation of Crohn's Disease Trajectories Using Change in Lémann Index: A Natural History Study.

Bhavana Bhagya Rao1, Ioannis E Koutroubakis, Claudia Ramos Rivers, Jean Frederic Colombel, Miguel Regueiro, Jason Swoger, Marc Schwartz, Leonard Baidoo, Jana Hashash, Arthur Barrie, Michael A Dunn, David G Binion.   

Abstract

BACKGROUND: Crohn's disease (CD) causes lifelong, progressive bowel damage, which may be quantified using the Lémann Index (LI). We aimed to analyze patterns of LI and its association with 5-year clinical course, in an independent cohort of CD patients.
METHODS: CD patients with 5-year follow-up from a registry maintained at a tertiary center were included. LI was calculated using a computerized metric from the first (LI1) and last (LI2) clinical encounters during the 5 years. Groups were created based on change in score (LI2-LI1) or the delta Lémann Index (DLI) as showing improvement, no change, or deterioration and used for association analysis with patterns of health care utilization, disease activity, and quality-of-life scores.
RESULTS: A total of 363 CD patients with 5-year follow-up formed the study population [median age 43 y (interquartile range (IQR), 33.3 to 55 y); 57% female; median disease duration 12 y (IQR, 3 to 19 y), overall surgical exposure 69.7%]. Median (IQR) LI1, LI2, and DLI were 8 (0 to 54), 9 (0 to 75), and 0 (-22 to -47), respectively. Patients were stratified based on DLI into 3 groups: A: DLI<0; B: DLI=0; and C: DLI>0; which comprised 16.5%, 35.3%, and 48.2% of the cohort, respectively. Patients in group C had significantly higher CD-related surgical exposure, health care utilization, and annual use of steroids and biological agents. DLI showed independent significant positive correlation with perianal disease (P=0.044), steroid use (P=0.007), clinical visits (P<0.001), and new surgeries (P=0.001).
CONCLUSIONS: Change in LI over time could function as a marker of disease trajectory for risk substratification and prognostication in CD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26646805     DOI: 10.1097/MCG.0000000000000463

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  4 in total

1.  Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease.

Authors:  Parakkal Deepak; Joel G Fletcher; Jeff L Fidler; John M Barlow; Shannon P Sheedy; Amy B Kolbe; William S Harmsen; Terry Therneau; Stephanie L Hansel; Brenda D Becker; Edward V Loftus; David H Bruining
Journal:  Inflamm Bowel Dis       Date:  2018-07-12       Impact factor: 5.325

2.  Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage.

Authors:  Hinaben Panchal; Mathilde Wagner; Manjil Chatterji; Bachir Taouli; Russell McBride; Jeromy R Patterson; Ryan Ungaro; Marla Dubinsky; Judy Cho; David B Sachar
Journal:  Dig Dis Sci       Date:  2019-01-03       Impact factor: 3.199

3.  The Cost of Crohn's Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories.

Authors:  Bhavana B Rao; Benjamin H Click; Ioannis E Koutroubakis; Claudia Ramos Rivers; Miguel Regueiro; Jason Swoger; Marc Schwartz; Jana Hashash; Arthur Barrie; Michael A Dunn; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

Review 4.  Advanced imaging techniques for small bowel Crohn's disease: what does the future hold?

Authors:  Inês Pita; Fernando Magro
Journal:  Therap Adv Gastroenterol       Date:  2018-02-12       Impact factor: 4.409

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.